Pertuzumab

This targeted therapy has been developed to help patients with HER2-positive breast cancer manage their condition more effectively. By harnessing the power of precise molecular interactions, Pertuzumab aims to slow down disease progression and improve patient outcomes.

How the Formula Works

The formulation of Pertuzumab involves a complex process where humanized antibodies are produced through recombinant DNA technology, allowing for a highly specific binding affinity to the HER2 protein.

Product Use Cases

• Administered via intravenous infusion every three weeks, with dosages tailored to individual patient needs.
• Typically packaged in vials containing 440 mg of lyophilized powder, requiring reconstitution before injection.
• Requires storage at temperatures below -20 °C to maintain efficacy and stability.